Healthcare [ 11/13 ] | Biotechnology [ 94/159 ]
NASDAQ | Common Stock
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States.
The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders.
Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies.
Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 13, 24 | -0.28 Increased by +53.33% | -0.3 Increased by +6.67% |
| Nov 14, 23 | -0.57 Increased by +3.39% | -0.42 Decreased by -35.71% |
| Aug 14, 23 | -0.61 Decreased by -19.61% | -0.47 Decreased by -29.79% |
| May 11, 23 | -0.5 Decreased by -150% | -0.53 Increased by +5.66% |
| Mar 9, 23 | -0.6 Decreased by -1.69% | -0.5 Decreased by -20% |
| Nov 10, 22 | -0.59 Decreased by -9.26% | -0.47 Decreased by -25.53% |
| Aug 15, 22 | -0.51 Increased by +5.56% | -0.56 Increased by +8.93% |
| May 16, 22 | -0.2 Decreased by -900% | -0.35 Increased by +42.86% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 0 Decreased by -100% | -16.12 M Increased by +51.06% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0 Decreased by -100% | -32.95 M Decreased by -4.46% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 354 K Decreased by -55.86% | -35.04 M Decreased by -26.38% | Decreased by -9.9 K% Decreased by -186.33% |
| Mar 31, 23 | 802 K Increased by 0% | -28.84 M Decreased by -131.32% | Decreased by -3.6 K% Decreased by -131.32% |
| Dec 31, 22 | 802 K Increased by 0% | -32.94 M Increased by +1.92% | Decreased by -4.11 K% Increased by +1.92% |
| Sep 30, 22 | 802 K Decreased by -52.18% | -31.55 M Decreased by -3.07% | Decreased by -3.93 K% Decreased by -115.52% |
| Jun 30, 22 | 802 K Decreased by -63.33% | -27.73 M Increased by +9.09% | Decreased by -3.46 K% Decreased by -147.91% |
| Mar 31, 22 | 802 K Decreased by -97.26% | 92.11 M Increased by +8.68 K% | Increased by +11.48 K% Increased by +313.75 K% |